Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study

• Published in: World journal of gastroenterology : WJG Vol. 27; no. 18; pp. 2177 - 2192
• Main Authors: Janczewska, Ewa, Kołek, Mateusz Franciszek, Lorenc, Beata, Klapaczyński, Jakub, Tudrujek-Zdunek, Magdalena, Sitko, Marek, Mazur, Włodzimierz, Zarębska-Michaluk, Dorota, Buczyńska, Iwona, Dybowska, Dorota, Czauż-Andrzejuk, Agnieszka, Berak, Hanna, Krygier, Rafał, Jaroszewicz, Jerzy, Citko, Jolanta, Piekarska, Anna, Dobracka, Beata, Socha, Łukasz, Deroń, Zbigniew, Laurans, Łukasz, Białkowska-Warzecha, Jolanta, Tronina, Olga, Adamek, Brygida, Tomasiewicz, Krzysztof, Simon, Krzysztof, Pawłowska, Malgorzata, Halota, Waldemar, Flisiak, Robert
• Format: Journal Article
• Language: English
• Published: Baishideng Publishing Group Inc 14-05-2021
• Subjects: Retrospective Cohort Study
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.v27.i18.2177

BACKGROUNDThe introduction of direct-acting antiviral drugs into clinical practice has revolutionized the treatment of chronic hepatitis C, making it highly effective and safe for patients. However, few researchers have analyzed the factors causing therapy failure in some patients. AIMTo analyze factors influencing the failure of direct antiviral drugs in the large, multicenter EpiTer-2 cohort in a real-world setting. METHODSThe study cohort consisted of patients with chronic hepatitis C treated at 22 Polish centers from 2016-2020. Data collected from the online EpiTer-2 database included the following: hepatitis C virus (HCV) genotype, stage of fibrosis, hematology and liver function parameters, Child-Turcotte-Pugh and Model for End-stage Liver Disease scores, prior antiviral therapy, concomitant diseases, and drugs used in relation to hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV) coinfections. Adverse events observed during the treatment and follow-up period were reported. Both standard and machine learning methods were used for statistical analysis. RESULTSDuring analysis, 12614 patients with chronic hepatitis C were registered, of which 11938 (mean age: 52 years) had available sustained virologic response (SVR) data [11629 (97%) achieved SVR and 309 (3%) did not]. Most patients (78.1%) were infected with HCV genotype 1b. Liver cirrhosis was diagnosed in 2974 patients, while advanced fibrosis (F3) was diagnosed in 1717 patients. We included patients with features of hepatic failure at baseline [ascites in 142 (1.2%) and encephalopathy in 68 (0.6%) patients]. The most important host factors negatively influencing treatment efficacy were liver cirrhosis, clinical and laboratory features of liver failure, history of hepatocellular carcinoma, and higher body mass index. Among viral factors, genotype 3 and viral load also exerted an influence on treatment efficacy. Classical statistical analysis revealed that treatment ineffectiveness seemed to be influenced by the male sex, which was not confirmed by the multivariate analysis using the machine learning algorithm (random forest). Coinfection with HBV (including patients with on-treatment reactivation of HBV infection) or HIV, extrahepatic manifestations, and renal failure did not significantly affect the treatment efficacy. CONCLUSIONIn patients with advanced liver disease, individualized therapy (testing for resistance-associated variants and response-guided treatment) should be considered to maximize the chance of achieving SVR.